Acetophenazine

CHEMBL1085 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

411.6 g/mol

LogP

2.6

Phase

4

An older antipsychotic medication from the phenothiazine class that was used to treat schizophrenia and other serious psychiatric conditions by blocking dopamine receptors in the brain. It reduces hallucinations, delusions, and disorganized thinking but carries a risk of movement-related side effects known as extrapyramidal symptoms, including tremors and involuntary muscle movements. It has been largely superseded by newer antipsychotic medications with improved tolerability profiles.

Peso molecular

411,6000 g/mol

LogP

2,60

TPSA

72,30 Å²

Regla de cinco de Lipinski

Cumple

Mecanismo de acción

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2

InChI

InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3

Molecular Formula

C23H29N3O2S

HBD / HBA

1 / 6

Enlaces Rotables

7

Átomos Pesados

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

An older antipsychotic medication from the phenothiazine class that was used to treat schizophrenia and other serious psychiatric conditions by blocking dopamine receptors in the brain. It reduces hallucinations, delusions, and disorganized thinking but carries a risk of movement-related side effects known as extrapyramidal symptoms, including tremors and involuntary muscle movements. It has been largely superseded by newer antipsychotic medications with improved tolerability profiles.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Acetophenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1085. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 17676. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Acetophenazine en PillFYI

Estructura

Datos Rápidos

Fórmula: C23H29N3O2S

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.